Xttrium Laboratories Revenue and Competitors

Xttrium Laboratories, Inc. has been a family owned and operated business for the past 75 years. It has seen many changes in that time period, but one aspect will always remain the same, our commitment to quality. The company''''s history began in 1932 when Joseph Creevy, an Executive VP of catalogue sales for Spiegel, and a group of physicians decided to open a full service treatment clinic for epilepsy patients. A staff of physicians, technicians, nurses, and pharmacists was formed, and Western Medical, Inc. opened its doors for the first time in the summer of 1932 at 415 W. Pershing Rd in the Chicago Bridgeport neighborhood. Once patients were stabilized on their medications, monthly prescriptions were mail ordered to the patients doorstep. Thus making, Western Medical one of the first mail order pharmacies in the United States. By the 1940s, Western Medical was treating over 1,000 patients. In 1932, Xttrium Labratories was established to produce an oral medicine with a time release formulation. In 1951, following the death of their father, Joseph Creevy's sons, Robert and Richard, took over the reins of both companies. Xttrium began expanding the business through entering the hospital market place with a product line, which included surgical scrub soaps, surgical instrument disinfectants, and several private label projects for a variety of companies. In 1982, Xttrium was awarded New Drug Applications (NDA) for a variety of Chlorhexidine Gluconate products, which became the cornerstone of their business. During the 1980s, Xttrium began to formulate and manufacture CHG based solutions for surgical scrub, and patient prep prior to surgery for major hospital products manufactures across the United States. These companies included Cardinal Health, Becton Dickenson, Sage Products, Purdue Frederick, Steris, Ballard, Medline, and Meritech. By the 1990s, Xttrium became the largest manufacturer of CHG solutions in the U.S. After the death of Robert Creevy in 1995, Kevin Creevy became president of the company and has run the company successfully ever since. In 2000, Xttrium signed a contract with Zila Pharmaceutical to manufacture their prescription oral rinse, Peridex. In 2002, Zila agreed to have Xttrium manufacture and sell the generic version of Peridex. As of 2006, Zila and Xttrium owned a 70%+ market share in the prescription oral rinse market place. Also in 2006, Xttrium will expand their product portfolio with 17 new drug products in the cough and cold category. Xttrium also plans to file 12 Abbreviated New Drug Applications for liquid generic pharmaceuticals and 4 Abbreviated New Drug Applications for solid generic pharmaceuticals in 2006 and 2007. Xttrium has a strong growth plan for its future in the generic drug market, but vows to maintain the solid reputation for excellence and quality built in its long history.